Cytotoxicity: How To Provide Operator Safety

Antibody-drug conjugates represent a remarkable convergence of targeting precision and cytotoxic power, but that power doesn't switch off at the manufacturing floor. The same payloads engineered to destroy cancer cells at nanogram concentrations pose genuine risks to every operator who handles them. From upstream processing through fill-finish and packaging, ADC manufacturing environments demand more than good intentions. They require rigorous occupational exposure limit assessments, facility designs built around containment, and handling protocols that leave nothing to chance.

This article examines the science behind ADC cytotoxicity, the exposure pathways that put operators at risk, and the facility and process controls that cGMP-compliant manufacturers rely on to protect their people without compromising product integrity. If your organization works with HPAPIs or is scaling ADC production, understanding these safety fundamentals is the foundation for everything else. Read the full article to learn what best-in-class ADC operator safety looks like in practice.